MSCLF Message Board Post 9833662 | iCo Therapeutics
home / stock / msclf / msclf message board
seadoo1968
(investorshub)
Posted on: Dec/24/2019 14:53:59
Source: investorshub
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=152963444
iCo Therapeutics Announces Completion of Sub-license Transfer and
News, Short Squeeze, Breakout and More Instantly...
-
– Investigational New Drug (IND) enabling preclinical and toxicology studies successfully completed – Initiation of a Phase 1 clinical trial of SAT-3247 anticipated in Q3 2024 Satellos Bioscience Inc. (“Satellos” or the “Company”) ...
-
–SAT-3247 treatment improved muscle repair and regeneration in canine model of DMD – SAT-3247 treatment also improved muscle force in this canine model of DMD – Satellos remains on track to initiate a Phase 1 clinical trial in Q3 2024 Satellos Bios...
-
– Frank Gleeson, Satellos CEO, to participate in a panel discussion titled "Research Row: PPMD Moving the Needle" on June 29, 2024 – Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company d...